The causes and treatment of pseudobulbar affect in ischemic stroke

Current Treatment Options in Cardiovascular Medicine

Volumn 10, Issue 3, 2008, Pages 216-222

  Balakrishnan, Preethi ^b   Rosen, Howard ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CISAPRIDE; CITALOPRAM; DEXTROMETHORPHAN; FLUOXETINE; GENERIC DRUG; IMIPRAMINE; MONOAMINE OXIDASE INHIBITOR; PHENOTHIAZINE DERIVATIVE; PIMOZIDE; PLACEBO; QUINIDINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SUMATRIPTAN; TRICYCLIC ANTIDEPRESSANT AGENT;

CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CLINICAL TRIAL; CONFUSION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DELIRIUM; DISEASE SEVERITY; DRUG ALCOHOL INTERACTION; DRUG CONTRAINDICATION; DRUG CROSS REACTIVITY; DRUG INDICATION; DRUG POTENTIATION; DRUG SAFETY; EMOTIONAL DISORDER; HEART ARRHYTHMIA; HISTORY OF MEDICINE; HUMAN; LOW DRUG DOSE; MENTAL INSTABILITY; NOMENCLATURE; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PSEUDOBULBAR AFFECT; QT INTERVAL; REVIEW; SEDATION; SEROTONIN SYNDROME; SIDE EFFECT; URINE RETENTION;

EID: 56349098191     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-008-0023-z     Document Type: Review

References (38)

1. Lawson IR, MacLeod RD: The use of imipramine ("Tofranil") and other psychotropic drugs in organic emotionalism. Br J Psychiatry 1969, 115:281-285.
2. House A, Dennis M, Molyneux A, et al.: Emotionalism after stroke. BMJ 1989, 298:991-994.
3. Dark FL, McGrath JJ, Ron MA: Pathological laughing and crying. Aust N Z J Psychiatry 1996, 30:472-479.
4. Lieberman A, Benson DF: Control of emotional expression in pseudobulbar palsy. A personal experience. Arch Neurol 1977, 34:717-719.
5. Darwin C: The Expression of Emotions in Man and Animals. New York: Appleton and Company; 1872.
6. Wilson SAK: Some problems in neurology: no. 2 pathological laughing and crying. J Neurol Psychopathol 1924, 4:299-333.
7. Gallagher JP: Pathologic laughter and crying in ALS: a search for their origin. Acta Neurol Scand 1989, 80:114-117.
8. Zeilig G, Drubach DA, Katz-Zeilig M, Karatinos J: Pathological laughter and crying in patients with closed traumatic brain injury. Brain Inj 1996, 10:591-597.
9. Schiffer R, Pope LE: Review of pseudobulbar affect including a novel and potential therapy. J Neuropsychiatry Clin Neurosci 2005, 17:447-454.
10. Kim JS, Choi S, Kwon SU, Seo YS: Inability to control anger or aggression after stroke. Neurology 2002, 58:1106-1108.
11. Poeck K: Pathophysiology of emotional disorders associated with brain damage. In Handbook of Clinical Neurology. Edited by Vinken PJ, Bruyn GW. Amsterdam: North Holland Publishing; 1969:343-367.
12. Kim JS, Choi-Kwon S: Poststroke depression and emotional incontinence: correlation with lesion location. Neurology 2000, 54:1805-1810.
13. Andersen G, Ingeman-Nielsen M, Vestergaard K, Riis JO: Pathoanatomic correlation between poststroke pathological crying and damage to brain areas involved in serotonergic neurotransmission. Stroke 1994, 25:1050-1052.
14. Achari AN, Colover J: Posterior fossa tumors with pathological laughter. JAMA 1976, 235:1469-1471.
15. Wisoff JH, Epstein FJ: Pseudobulbar palsy after posterior fossa operation in children. Neurosurgery 1984, 15:707-709.
16. Tei H, Sakamoto Y: Pontine infarction due to basilar artery stenosis presenting as pathological laughter. Neuroradiology 1997, 39:190-191.
17. Bhatjiwale MG, Nadkarni TD, Desai KI, Goel A: Pathological laughter as a presenting symptom of massive trigeminal neuromas: report of four cases. Neurosurgery 2000, 47:469-471; discussion 471-472.
18. Parvizi J, Anderson SW, Martin CO, et al.: Pathological laughter and crying: a link to the cerebellum. Brain 2001, 124(Pt 9):1708-1719.
19. Arciniegas DB, Lauterbach EC, Anderson KE, et al.: The differential diagnosis of pseudobulbar affect (PBA). Distinguishing PBA among disorders of mood and affect. Proceedings of a roundtable meeting. CNS Spectr 2005, 10:1-14; quiz 15-16.
20. Moore SR, Gresham LS, Bromberg MB, et al.: A self report measure of affective lability. J Neurol Neurosurg Psychiatry 1997, 63:89-93.
21. Nahas Z, Arlinghaus KA, Kotrla KJ, et al.: Rapid response of emotional incontinence to selective serotonin reuptake inhibitors. J Neuropsychiatry Clin Neurosci 1998, 10:453-455.
22. Allman P, Hope RA, Fairburn CG: Emotionalism following brain damage: a complex phenomenon. Postgrad Med J 1990, 66:818-821.
23. Cummings JL, Arciniegas DB, Brooks BR, et al.: Defining and diagnosing involuntary emotional expression disorder. CNS Spectr 2006, 11(Suppl 6):1-7.
24. Kim SW, Shin IS, Kim JM, et al.: Mirtazapine treatment for pathological laughing and crying after stroke. Clin Neuropharmacol 2005, 28:249-251.
25. Udaka F, Yamao S, Nagata H, et al.: Pathologic laughing and crying treated with levodopa. Arch Neurol 1984, 41:1095-1096.
26. Wolf JK, Santana HB, Thorpy M: Treatment of "emotional incontinence" with levodopa. Neurology 1979, 29:1435-1436.
27. Ramasubbu R: Lamotrigine treatment for post-stroke pathological laughing and crying. Clin Neuropharmacol 2003, 26:233-235.
28. Schiffer RB, Herndon RM, Rudick RA: Treatment of pathologic laughing and weeping with amitriptyline. N Engl J Med 1985, 312:1480-1482.
29. Robinson RG, Parikh RM, Lipsey JR, et al.: Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. Am J Psychiatry 1993, 150:286-293.
30. Murai T, Barthel H, Berrouschot J, et al.: Neuroimaging of serotonin transporters in post-stroke pathological crying. Psychiatry Res 2003, 123:207-211.
31. Seliger GM, Hornstein A, Flax J, et al.: Fluoxetine improves emotional incontinence. Brain Inj 1992, 6:267-270.
32. Andersen G, Vestergaard K, Riis JO: Citalopram for post-stroke pathological crying. Lancet 1993, 342:837-839.
33. Burns A, Russell E, Stratton-Powell H, et al.: Sertraline in stroke-associated lability of mood. Int J Geriatr Psychiatry 1999, 14:681-685.
34. Brooks BR, Thisted RA, Appel SH, et al.: Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology 2004, 63:1364-1370.
35. Panitch HS, Thisted RA, Smith RA, et al.: Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol 2006, 59:780-787.
36. Palmer GC: Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies. Curr Drug Targets 2001, 2:241-271.
37. Su TP, Hayashi T: Understanding the molecular mechanism of sigma-1 receptors: towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction. Curr Med Chem 2003, 10:2073-2080.
38. Kamei H, Kameyama T, Nabeshima T: Effects of sigma receptor ligands on conditioned fear stress. Methods Find Exp Clin Pharmacol 1998, 20:613-618.